Erscheinung:11.12.2019, Stand:updated on 02.01.2020 | Topic Measures Elanix Biotechnologies AG: BaFin imposes coercive fines
On 26 November 2019, BaFin imposed coercive fines on Elanix Biotechnologies AG in the amount of EUR 565,000 to enforce an order concerning compliance with the financial reporting requirements under section 114 et seq. of the Securities Trading Act (Wertpapierhandelsgesetz – WpHG).
As BaFin has already reported, Elanix Biotechnologies AG contravened the requirements under section 114 (1) sentences 2 and 3 of the WpHG with respect to the annual financial information for the financial year 2018 as well as section 115 (1) of the WpHG with respect to the half-yearly financial report for the financial year 2018 and BaFin issued a notice on 2 September 2019 to order the company to comply with these requirements. The company did not comply with this order.
The notice imposing the coercive fine is immediately enforceable but not yet final and binding.
Update (02.01.2020):
On 20 December 2019, the company lodged an objection against the notice imposing a coercive fine.
